{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:52:40Z","timestamp":1781563960369,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40290-019-00281-4","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T10:07:19Z","timestamp":1558433239000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin\/Linagliptin Data"],"prefix":"10.1007","volume":"33","author":[{"given":"Angelo","family":"Del Parigi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dacheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"281_CR1","unstructured":"World Health Organization. Global report on diabetes. 2016. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/204871\/1\/9789241565257_eng.pdf\n                    \n                  . Accessed 14 Mar 2017."},{"issue":"2","key":"281_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1124\/pr.110.003533","volume":"63","author":"Q Ma","year":"2011","unstructured":"Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63(2):437\u201359.","journal-title":"Pharmacol Rev."},{"issue":"1","key":"281_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/CS-2018-0535","volume":"25","author":"AJ Garber","year":"2019","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142019 executive summary. Endocr Pract. 2019;25(1):69\u2013100.","journal-title":"Endocr Pract."},{"key":"281_CR4","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142019. Diabetes Care. 2019;42(Suppl 1):S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"issue":"3","key":"281_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.clinthera.2006.03.005","volume":"28","author":"KM Fox","year":"2006","unstructured":"Fox KM, Gerber RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006;28(3):388\u201395.","journal-title":"Clin Ther."},{"issue":"4","key":"281_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pcd.2011.07.001","volume":"5","author":"H Khan","year":"2011","unstructured":"Khan H, Lasker SS, Chowdhury TA. Exploring reasons for very poor glycaemic control in patients with type 2 diabetes. Prim Care Diabetes. 2011;5(4):251\u20135.","journal-title":"Prim Care Diabetes."},{"issue":"8","key":"281_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2337\/dc12-2258","volume":"36","author":"S Stark Casagrande","year":"2013","unstructured":"Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010. Diabetes Care. 2013;36(8):2271\u20139.","journal-title":"Diabetes Care."},{"issue":"14","key":"281_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMra1814259","volume":"380","author":"A Rajkomar","year":"2019","unstructured":"Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347\u201358.","journal-title":"N Engl J Med."},{"key":"281_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.csbj.2016.12.005","volume":"15","author":"I Kavakiotis","year":"2017","unstructured":"Kavakiotis I, Tsave O, Salifoglou A, Maglaveras N, Vlahavas I, Chouvarda I. Machine learning and data mining methods in diabetes research. Comput Struct Biotechnol J. 2017;15:104\u201316.","journal-title":"Comput Struct Biotechnol J."},{"issue":"9","key":"281_CR10","doi-asserted-by":"publisher","first-page":"E2208","DOI":"10.3390\/molecules23092208","volume":"23","author":"R Chen","year":"2018","unstructured":"Chen R, Liu X, Jin S, Lin J, Liu J. Machine learning for drug-target interaction prediction. Molecules. 2018;23(9):E2208.","journal-title":"Molecules."},{"issue":"20","key":"281_CR11","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1161\/CIRCULATIONAHA.115.001593","volume":"132","author":"RC Deo","year":"2015","unstructured":"Deo RC. Machine learning in medicine. Circulation. 2015;132(20):1920\u201330.","journal-title":"Circulation."},{"issue":"4","key":"281_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/svn-2017-000101","volume":"2","author":"F Jiang","year":"2017","unstructured":"Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230\u201343.","journal-title":"Stroke Vasc Neurol."},{"issue":"10","key":"281_CR13","doi-asserted-by":"publisher","first-page":"e0140827","DOI":"10.1371\/journal.pone.0140827","volume":"10","author":"L Cai","year":"2015","unstructured":"Cai L, Wu H, Li D, Zhou K, Zou F. Type 2 diabetes biomarkers of human gut microbiota selected via iterative sure independent screening method. PLoS One. 2015;10(10):e0140827.","journal-title":"PLoS One."},{"issue":"1","key":"281_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1109\/JBHI.2015.2396520","volume":"20","author":"BJ Lee","year":"2016","unstructured":"Lee BJ, Kim JY. Identification of type 2 diabetes risk factors using phenotypes consisting of anthropometry and triglycerides based on machine learning. IEEE J Biomed Health Inform. 2016;20(1):39\u201346.","journal-title":"IEEE J Biomed Health Inform."},{"issue":"4","key":"281_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1530\/EJE-10-0649","volume":"163","author":"M Hische","year":"2010","unstructured":"Hische M, Luis-Dominguez O, Pfeiffer AF, Schwarz PE, Selbig J, Spranger J. Decision trees as a simple-to-use and reliable tool to identify individuals with impaired glucose metabolism or type 2 diabetes mellitus. Eur J Endocrinol. 2010;163(4):565\u201371.","journal-title":"Eur J Endocrinol."},{"key":"281_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jbi.2015.02.001","volume":"54","author":"KJ Wang","year":"2015","unstructured":"Wang KJ, Adrian AM, Chen KH, Wang KM. An improved electromagnetism-like mechanism algorithm and its application to the prediction of diabetes mellitus. J Biomed Inform. 2015;54:220\u20139.","journal-title":"J Biomed Inform."},{"issue":"6","key":"281_CR17","doi-asserted-by":"publisher","first-page":"e98587","DOI":"10.1371\/journal.pone.0098587","volume":"9","author":"R Casanova","year":"2014","unstructured":"Casanova R, Saldana S, Chew EY, Danis RP, Greven CM, Ambrosius WT. Application of random forests methods to diabetic retinopathy classification analyses. PLoS One. 2014;9(6):e98587.","journal-title":"PLoS One."},{"issue":"2","key":"281_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s13300-014-0090-y","volume":"5","author":"S Bujac","year":"2014","unstructured":"Bujac S, Del Parigi A, Sugg J, et al. Patient characteristics are not associated with clinically important differential response to dapagliflozin: a staged analysis of phase 3 data. Diabetes Ther. 2014;5(2):471\u201382.","journal-title":"Diabetes Ther."},{"issue":"1","key":"281_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1932296815620200","volume":"10","author":"JP Anderson","year":"2016","unstructured":"Anderson JP, Parikh JR, Shenfield DK, et al. Reverse engineering and evaluation of prediction models for progression to type 2 diabetes: an application of machine learning using electronic health records. J Diabetes Sci Technol. 2016;10(1):6\u201318.","journal-title":"J Diabetes Sci Technol."},{"key":"281_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Machine Learning. 2001;45:5\u201332.","journal-title":"Machine Learning."},{"key":"281_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.talanta.2013.03.039","volume":"110","author":"JH Huang","year":"2013","unstructured":"Huang JH, He RH, Yi LZ, Xie HL, Cao DS, Liang YZ. Exploring the relationship between 5\u2019AMP-activated protein kinase and markers related to type 2 diabetes mellitus. Talanta. 2013;110:1\u20137.","journal-title":"Talanta."},{"issue":"3","key":"281_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2337\/dc14-2365","volume":"38","author":"A Lewin","year":"2015","unstructured":"Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394\u2013402.","journal-title":"Diabetes Care."},{"issue":"3","key":"281_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc14-2364","volume":"38","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384\u201393.","journal-title":"Diabetes Care."},{"key":"281_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-84858-7","volume-title":"The elements of statistical learning: data mining, inference, and prediction","author":"TTR Hastie","year":"2009","unstructured":"Hastie TTR, Friedman J. The elements of statistical learning: data mining, inference, and prediction. 2nd ed. Berlin: Springer; 2009.","edition":"2"},{"key":"281_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.csda.2006.12.030","volume":"52","author":"CBA Strobl","year":"2007","unstructured":"Strobl CBA, Augustin T. Unbiased split selection for classification trees based on the Gini Index. Comput Stat Data Anal. 2007;52:483\u2013501.","journal-title":"Comput Stat Data Anal."},{"issue":"3","key":"281_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.diabres.2015.02.034","volume":"108","author":"B Balkau","year":"2015","unstructured":"Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD. Predictors of HbA1c over 4\u00a0years in people with type 2 diabetes starting insulin therapies: the CREDIT study. Diabetes Res Clin Pract. 2015;108(3):432\u201340.","journal-title":"Diabetes Res Clin Pract."},{"key":"281_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.diabres.2016.08.011","volume":"121","author":"H Bihan","year":"2016","unstructured":"Bihan H, Ng WL, Magliano DJ, Shaw JE. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: a systematic review. Diabetes Res Clin Pract. 2016;121:27\u201334.","journal-title":"Diabetes Res Clin Pract."},{"issue":"7","key":"281_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dme.12688","volume":"32","author":"DP Martono","year":"2015","unstructured":"Martono DP, Lub R, Lambers Heerspink HJ, Hak E, Wilffert B, Denig P. Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review. Diabet Med. 2015;32(7):853\u201364.","journal-title":"Diabet Med."},{"key":"281_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.csbj.2016.12.005","volume":"15","author":"I Kavakiotis","year":"2017","unstructured":"Kavakiotis I, Tsave O, Salifoglou A, Maglaveras N, Vlahavas I, Chouvarda I. Machine learning and data mining methods in diabetes research. Comput Struct Biotechnol J. 2017;15:104\u201316.","journal-title":"Comput Struct Biotechnol J."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-019-00281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40290-019-00281-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-019-00281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T23:23:22Z","timestamp":1589844202000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40290-019-00281-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1007\/s40290-019-00281-4","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"20 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The studies were sponsored by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; this analysis was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). The authors received no direct compensation related to the development of the manuscript. Writing support was provided by Jennifer Garrett, MBBS, of Envision Scientific Solutions, which was contracted and compensated by BIPI for this service. Open access was funded by BIPI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Richard Pratley has received research funding from Lexicon Pharmaceuticals, Lilly, Merck, Novo Nordisk, Sanofi Aventis US, LLC, and Takeda; speaker fees from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Takeda; and consultancy fees from AstraZeneca, Boehringer Ingelheim, Janssen Scientific Affairs, LLC, Ligand Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Sanofi Aventis US, LLC, and Takeda. All honoraria and fees are directed to a non-profit organization; he received no direct compensation. Dacheng Liu and Wenbo Tang are employees of Boehringer Ingelheim. Angelo Del Parigi and Christopher Lee were employees of Boehringer Ingelheim at the time these studies were conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"In the studies analyzed, all procedures performed involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"This work was previously presented as a poster at the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, Austin, TX, USA, 3\u20137 May 2017.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Publication"}}]}}